kDepartment of Internal Medicine, Universidad de La Laguna, and Department of Cardiology, Hospital Universitario de Canarias, Instituto de Investigación Sanitaria de Canarias, Tenerife, Spain ...
Guidelines unanimously recommend quadruple therapy for patients with heart failure with reduced ejection fraction (HFrEF), yet direct comparative evidence is lacking to recommend a specific order of ...
Canadian VIGOUR Centre, University of Alberta, Edmonton. (R.M., N.S., J.A.E.) Saw Swee Hock School of Public Health and National University of Singapore and National ...
The Phase III VICTOR trial (NCT05093933) evaluated Verquvo in patients with stable, well-treated chronic heart failure and reduced ejection fraction without a recent worsening heart failure event.
Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality, new myocardial infarction (MI) and heart failure (HF) compared with no beta-blocker therapy in the subgroup of ...
Who wouldn't be inspired to train with a smiling Muay Thai trainer? Photo / Ash Jurberg White Lotus may have us dreaming of a millionaire’s holiday in Thailand, but Ash Jurberg discovers you can find ...
Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet RAHWAY, N.J., ...
Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet Merck (NYSE: MRK) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback